-+ 0.00%
-+ 0.00%
-+ 0.00%
Lakewood-Amedex Reports Nu-3 Activity Against Drug-Resistant Bacteria in Laboratory Study
Share
Listen to the news
Lakewood-Amedex Reports Nu-3 Activity Against Drug-Resistant Bacteria in Laboratory Study
  • Lakewood-Amedex Biotherapeutics will present Nu-3 antimicrobial research at IDWeek 2026 on October 22, 2026.
  • Laboratory findings showed rapid activity against resistant bacteria, with a low potential for resistance development.
  • Nu-3 is undergoing a Phase 2a trial as a topical treatment for mildly infected diabetic foot ulcers.
  • Topline trial results are expected in the first quarter of 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lakewood-Amedex Biotherapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY77233) on October 21, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending